Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Paycor Announces Third Quarter Fiscal Year 2023 Financial Results

Published

on

<!– Name:DistributionId Value:8836407 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:8700 –> <!– Name:CustomerId Value:1105308 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:63238f51-5c5b-4e4d-afe0-554b1c8b3a56 –>

  • Q3 Total revenues of $161.5 million, an increase of 32% year-over-year, while expanding margins
  • Q3 Recurring revenue of $150.8 million, an increase of 23% year-over-year, and the sixth consecutive quarter of achieving 20%+ revenue growth
  • Raises FY’23 revenue and Adjusted operating income guidance $5 million and $3 million, respectively, year-over-year at the top end of the range

CINCINNATI , May 10, 2023 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (“HCM”) software, today announced financial results for the third quarter of fiscal year 2023, which ended March 31, 2023.

“Paycor posted robust 32% revenue growth year-over-year, reflecting continued strong demand for our innovative HCM suite and consistent execution of our go to market strategy as we expand nationally,” said Raul Villar, Jr., Chief Executive Officer of Paycor. “Paycor’s ability to invest in differentiated cloud technology that enables all leaders to be more effective while expanding margins for the fourth consecutive quarter demonstrates the scalability of our business model.”

“This quarter we launched powerful new analytics and automation capabilities that empower frontline leaders to drive business results. We continue to advance the platform with leading-edge capabilities, such as leveraging artificial intelligence to optimize sentiment in performance reviews and acquiring a behavioral science-based microlearning platform that will enable leaders to develop their employees more effectively.”

Third Quarter Fiscal Year 2023 Financial Highlights

  • Total revenues were $161.5 million, compared to $122.6 million for the third quarter of fiscal year 2022.
  • Operating loss was $8.0 million, compared to $23.5 million for the third quarter of fiscal year 2022.
  • Adjusted operating income* was $39.1 million, compared to $24.7 million for the third quarter of fiscal year 2022.
  • Net loss attributable to Paycor HCM was $7.3 million, compared to $16.7 million for the third quarter of fiscal year 2022.
  • Adjusted net income attributable to Paycor HCM* was $31.6 million, compared to $18.6 million for the third quarter of fiscal year 2022.

*Adjusted operating income and adjusted net income attributable to Paycor HCM are non-GAAP financial measures. Please see the discussion below under the heading “Non-GAAP Financial Measures” and the reconciliations at the end of this press release for information concerning these and other non-GAAP financial measures.

Third Quarter and Recent Business Highlights

  • Acquired Verb, a modern behavioral science-based microlearning solution to develop frontline leaders and their teams. Paycor plans to integrate Verb into its HCM platform to help organizations inspire positive, sustainable behavioral change through personalized development journeys.
  • Building on artificial intelligence-driven innovation such as Paycor Smart Sourcing and Predictive Resignation, Paycor introduced its existing natural language processing and sentiment analysis engines into Performance Reviews to provide frontline leaders real time feedback on the language used in evaluations to foster a more humanized, engaging work culture.
  • To further support frontline leaders, we deployed Industry Reports to provide quick access to important insights about their business.
  • Won six Titan Business Intelligence Awards spanning Paycor’s best-in-class Talent Management solution, Paycor Smart Sourcing, and insightful analytics that help frontline leaders optimize business decisions.

Business Outlook

Based on information as of today, May 10, 2023, Paycor is issuing the following financial guidance:

Fourth Quarter Ending June 30, 2023:

  • Total revenues in the range of $135-$137 million.
  • Adjusted operating income* in the range of $13-$14 million.

Fiscal Year Ending June 30, 2023:

  • Total revenues in the range of $548-$550 million.
  • Adjusted operating income* in the range of $80-$81 million.

*We are unable to reconcile forward-looking adjusted operating income to forward-looking loss from operations, the most closely comparable GAAP financial measure because the information needed to provide a complete reconciliation is unavailable at this time without unreasonable effort.

Conference Call Information

Paycor will host a conference call today, May 10, 2023, at 5:00 p.m. Eastern Time to discuss its financial results and guidance. To access this call, dial 1-877-407-4018 (domestic) or 1-201-689-8471 (international). The access code is 13735321. A live webcast and replay of the event will be available on the Paycor Investor Relations website at investors.paycor.com.

About Paycor

Paycor’s human capital management (HCM) platform modernizes every aspect of people management, from recruiting, onboarding, and payroll to career development and retention, but what really sets us apart is our focus on leaders. For more than 30 years, we’ve been listening to and partnering with leaders, so we know what they need; a unified HR platform, easy integration with third party apps, powerful analytics, talent development tools, and configurable technology that supports specific industry needs. That’s why more than 30,000 customers trust Paycor to help them solve problems and achieve their goals.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including statements regarding our future results of operations and financial position, our business outlook, our business strategy and plans, our objectives for future operations, and any statements of a general economic or industry specific nature, are forward-looking statements. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” “outlook,” “potential,” “targets,” “contemplates,” or the negative or plural of these words and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022, as well as in our other filings with the Securities and Exchange Commission. We believe that these risks include, but are not limited to: our ability to manage our growth effectively; the potential breach of our security measures or unauthorized access to our customers’ or their employees’ personal data; the expansion and retention of our direct sales force with qualified and productive persons and the related effects on the growth of our business; the impact on customer expansion and retention if implementation, user experience, customer service, or performance relating to our solutions is not satisfactory; the timing of payments made to employees and taxing authorities relative to the timing of when a customer’s electronic funds transfers are settled to our account; future acquisitions of other companies’ businesses, technologies, or customer portfolios; the continued service of our key executives; our ability to innovate and deliver high-quality, technologically advanced products and services; our ability to attract and retain qualified personnel; the proper operation of our software; our relationships with third parties; the ongoing effects of inflation, supply chain disruptions, labor shortages and other adverse macroeconomic conditions in the market in which we and our customers operate; the impact of an economic downturn or recession in the United States or global economy; and the other risks described in our Annual Report on Form 10-K for the year ended June 30, 2022, as well as in our other filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations and assumptions reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We undertake no obligation to publicly update any forward-looking statement after the date of this report, whether as a result of new information, future developments or otherwise, or to conform these statements to actual results or revised expectations, except as may be required by law.

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present the following non-GAAP financial measures in this press release and on the related teleconference call: adjusted gross profit, adjusted gross profit margin, adjusted operating income, adjusted operating income margin, adjusted sales and marketing expense, adjusted general and administrative expense, adjusted research and development expense, adjusted net income attributable to Paycor HCM, Inc. and adjusted net income attributable to Paycor HCM, Inc. per share. Management believes these non-GAAP measures are useful in evaluating our core operating performance and trends to prepare and approve our annual budget, and to develop short-term and long-term operating plans. Management believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results. We define (i) adjusted gross profit as gross profit before amortization of intangible assets, stock-based compensation expense, and other certain corporate expenses, in each case that are included in costs of recurring revenues, (ii) adjusted gross profit margin as adjusted gross profit divided by total revenues, (iii) adjusted operating income as loss from operations before amortization of acquired intangible assets and naming rights, stock-based compensation expense, exit cost due to exiting leases of certain facilities and other certain corporate expenses, such as costs related to acquisitions, (iv) adjusted operating income margin as adjusted operating income divided by total revenues, (v) adjusted sales and marketing expense as sales and marketing expenses before amortization of naming rights, stock-based compensation expense and other certain corporate expenses, (vi) adjusted general and administrative expense as general and administrative expenses before amortization of acquired intangible assets, stock-based compensation expense, exit cost due to exiting leases of certain facilities and other certain corporate expenses, (vii) adjusted research and development expense as research and development expenses before stock-based compensation expense and other certain corporate expenses, (viii) adjusted net income attributable to Paycor HCM, Inc. as loss before benefit for income taxes after adjusting for amortization of acquired intangible assets and naming rights, accretion expense associated with the naming rights, stock-based compensation expense, gain or loss on the extinguishment of debt, exit costs due to exiting leases of certain facilities and other certain corporate expenses, such as costs related to acquisitions, all of which are tax effected by applying an adjusted effective income tax rate and (ix) adjusted net income attributable to Paycor HCM, Inc. per share as adjusted net income attributable to Paycor HCM, Inc. divided by adjusted shares outstanding. Adjusted shares outstanding includes potentially dilutive securities excluded from the GAAP dilutive net loss per share calculation.

Other certain corporate expenses presented include one-time costs related to secondary offerings, restructuring costs, professional, consulting and other costs, transaction expenses and other costs, costs associated with becoming a public company and implementation of a new enterprise-resource planning system.

The non-GAAP financial measures presented in this press release and discussed on the related teleconference call are not measures of financial performance under GAAP and should not be considered a substitute for gross profit, gross margin, operating income, operating income margin, sales and marketing expense, general and administrative expense, research and development expense, net income attributable to Paycor HCM, Inc. and diluted net income attributable to Paycor HCM, Inc. per share. Non-GAAP financial measures have limitations as analytical tools, and when assessing our operating performance, you should not consider them in isolation, or as a substitute for analysis of our results as reported under GAAP. The non-GAAP financial measures that we present may not be comparable to similarly titled measures used by other companies. A reconciliation is provided below under “Reconciliations of Non-GAAP Measures to GAAP Measures,” for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP.

Investor Relations:
Rachel White
513-954-7388
[email protected]

Media Relations:
Carly Pennekamp
513-954-7282
[email protected]

Paycor HCM, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)  

  March 31,
2023
  June 30,
2022
Assets (Unaudited)    
Current assets:      
Cash and cash equivalents $ 82,858     $ 133,041  
Accounts receivable, net   30,506       21,511  
Deferred contract costs   49,982       37,769  
Prepaid expenses   17,256       9,421  
Other current assets   3,533       1,874  
   Current assets before funds held for clients   184,135       203,616  
Funds held for clients   1,258,249       1,715,916  
   Total current assets   1,442,384       1,919,532  
Property and equipment, net   31,404       31,675  
Operating lease right-of-use assets   17,500        
Goodwill   761,425       750,155  
Intangible assets, net   282,956       263,069  
Capitalized software, net   49,819       40,002  
Long-term deferred contract costs   153,519       125,705  
Other long-term assets   3,991       1,179  
   Total assets $ 2,742,998     $ 3,131,317  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $ 20,987     $ 13,945  
Accrued expenses and other current liabilities   18,954       13,907  
Accrued payroll and payroll related expenses   36,515       44,592  
Deferred revenue   12,724       11,742  
   Current liabilities before client fund obligations   89,180       84,186  
Client fund obligations   1,260,057       1,719,047  
   Total current liabilities   1,349,237       1,803,233  
Deferred income taxes   21,848       31,895  
Long-term operating leases   16,644        
Other long-term liabilities   70,005       11,458  
   Total liabilities   1,457,734       1,846,586  
Commitments and contingencies      
Stockholders’ equity:      
Common stock $0.001 par value per share, 500,000,000 shares authorized, 176,440,422 shares outstanding at March 31, 2023 and 174,909,539 shares outstanding at June 30, 2022   176       175  
Treasury stock, at cost, 10,620,260 shares at March 31, 2023 and June 30, 2022   (245,074 )     (245,074 )
Preferred stock, $0.001 par value, 50,000,000 shares authorized, — shares outstanding at March 31, 2023 and June 30, 2022          
Additional paid-in capital   1,991,298       1,926,800  
Accumulated deficit   (459,244 )     (395,389 )
Accumulated other comprehensive loss   (1,892 )     (1,781 )
   Total stockholders’ equity   1,285,264       1,284,731  
   Total liabilities and stockholders’ equity $ 2,742,998     $ 3,131,317  

 Paycor HCM, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share amounts)

  Three Months Ended   Nine Months Ended
  March 31,   March 31,
    2023       2022       2023       2022  
Revenues:              
Recurring and other revenue $ 150,757     $ 122,189     $ 389,908     $ 317,334  
Interest income on funds held for clients   10,725       408       22,741       1,062  
   Total revenues   161,482       122,597       412,649       318,396  
Cost of revenues   49,323       41,157       138,692       127,850  
   Gross profit   112,159       81,440       273,957       190,546  
Operating expenses:              
Sales and marketing   55,499       41,487       155,607       127,957  
General and administrative   51,033       54,090       151,405       141,963  
Research and development   13,658       9,324       39,935       30,120  
   Total operating expenses   120,190       104,901       346,947       300,040  
   Loss from operations   (8,031 )     (23,461 )     (72,990 )     (109,494 )
Other (expense) income:              
Interest expense   (1,970 )     (101 )     (3,461 )     (448 )
Other   2,003       (12 )     2,514       1,540  
Loss before benefit for income taxes   (7,998 )     (23,574 )     (73,937 )     (108,402 )
Income tax benefit   (658 )     (6,876 )     (10,082 )     (24,204 )
Net loss   (7,340 )     (16,698 )     (63,855 )     (84,198 )
Less: Accretion of redeemable noncontrolling interests                     11,621  
Net loss attributable to Paycor HCM, Inc. $ (7,340 )   $ (16,698 )   $ (63,855 )   $ (95,819 )
Basic and diluted net loss attributable to Paycor HCM, Inc. per share $ (0.04 )   $ (0.10 )   $ (0.36 )   $ (0.56 )
Weighted average common shares outstanding:              
Basic and diluted   176,306,017       174,819,649       175,879,962       171,881,617  
               

Paycor HCM, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)

  Nine Months Ended  
  March 31,  
    2023       2022    
Cash flows from operating activities:        
Net loss $ (63,855 )   $ (84,198 )  
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation   3,571       5,113    
Amortization of intangible assets and software   92,727       95,556    
Amortization of deferred contract costs   33,246       22,330    
Stock-based compensation expense   58,019       55,321    
Deferred tax benefit   (10,287 )     (24,227 )  
Bad debt expense   3,233       1,655    
Loss (gain) on sale of investments   232       (9 )  
Gain on installment sale         (1,359 )  
Loss on foreign currency exchange   381       101    
Loss on lease exit   950       9,055    
Naming rights accretion expense   3,198          
Change in fair value of deferred consideration         (138 )  
Other   (930 )     66    
Changes in assets and liabilities, net of effects from acquisitions:        
Accounts receivable   (12,063 )     (5,391 )  
Prepaid expenses and other assets   (6,510 )     (5,195 )  
Accounts payable   6,229       (160 )  
Accrued liabilities and other   (19,602 )     618    
Deferred revenue   1,119       943    
Deferred contract costs   (73,273 )     (58,450 )  
Net cash provided by operating activities   16,385       11,631    
Cash flows from investing activities:        
Purchases of client funds available-for-sale securities   (365,196 )     (178,362 )  
Proceeds from sale and maturities of client funds available-for-sale securities   259,097       127,603    
Purchase of property and equipment   (3,285 )     (1,861 )  
Proceeds from note receivable on installment sale         3,040    
Acquisition of intangible assets   (18,842 )     (4,640 )  
Acquisition of Talenya Ltd., net of cash acquired   (18,793 )        
Internally developed software costs   (30,600 )     (22,667 )  
Net cash used in investing activities   (177,619 )     (76,887 )  
Cash flows from financing activities:        
Net change in cash and cash equivalents held to satisfy client funds obligations   (453,685 )     1,204,091    
Payment of deferred consideration         (2,752 )  
Proceeds from line-of-credit         3,500    
Repayments of line-of-credit         (52,600 )  
Repayments of debt and capital lease obligations   (211 )        
Proceeds from the issuance of common stock sold in the IPO, net of offering costs and underwriting discount         454,915    
Redemption of Redeemable Series A Preferred Stock (acquisition of noncontrolling interest)         (260,044 )  
Withholding taxes paid related to net share settlements   (2,150 )        
Proceeds from exercise of stock options   345          
Proceeds from employee stock purchase plan   8,285       3,186    
Other financing activities         (395 )  
Net cash (used in) provided by financing activities   (447,416 )     1,349,901    
Impact of foreign exchange on cash and cash equivalents   (15 )     18    
Net change in cash, cash equivalents, restricted cash and short-term investments, and funds held for clients   (608,665 )     1,284,663    
Cash, cash equivalents, restricted cash and short-term investments, and funds held for clients, beginning of period   1,682,923       560,000    
Cash, cash equivalents, restricted cash and short-term investments, and funds held for clients, end of period $ 1,074,258     $ 1,844,663    
Supplemental disclosure of non-cash investing, financing and other cash flow information:        
Capital expenditures in accounts payable $ 2     $ 25    
Cash paid for interest         154    
Reconciliation of cash, cash equivalents, restricted cash and short-term investments, and funds held for clients to the Consolidated Balance Sheets        
Cash and cash equivalents $ 82,858     $ 134,004    
Funds held for clients   991,400       1,710,659    
Total cash, cash equivalents, restricted cash and short-term investments, and funds held for clients $ 1,074,258     $ 1,844,663    

Reconciliations of Non-GAAP Measures to GAAP Measures

Adjusted Gross Profit and Adjusted Gross Profit Margin (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Gross Profit* $ 112,159     $ 81,440     $ 273,957     $ 190,546  
Gross Profit Margin   69.5 %     66.4 %     66.4 %     59.8 %
Amortization of intangible assets   1,358       1,433       3,786       18,017  
Stock-based compensation expense   2,440       1,710       6,755       5,205  
Adjusted Gross Profit* $ 115,957     $ 84,583     $ 284,498     $ 213,768  
Adjusted Gross Profit Margin   71.8 %     69.0 %     68.9 %     67.1 %

*    Gross Profit and Adjusted Gross Profit are burdened by depreciation expense of $0.4 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively, and $1.3 million and $2.0 million for the nine months ended March 31, 2023 and 2022, respectively. Gross Profit and Adjusted Gross Profit are burdened by amortization of capitalized software of $7.2 million and $5.8 million for the three months ended March 31, 2023 and 2022, respectively, and $20.3 million and $16.0 million for the nine months ended March 31, 2023 and 2022, respectively. Gross Profit and Adjusted Gross Profit are burdened by amortization of deferred contract costs of $6.8 million and $4.6 million for the three months ended March 31, 2023 and 2022, respectively, and $18.6 million and $12.2 million for the nine months ended March 31, 2023 and 2022, respectively.

Adjusted Operating Income (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Loss from Operations $ (8,031 )   $ (23,461 )   $ (72,990 )   $ (109,494 )
Operating Margin (5.0)%   (19.1)%   (17.7)%   (34.4)%
Amortization of intangible assets   24,467       22,136       72,410       79,548  
Stock-based compensation expense   20,384       16,294       58,019       55,321  
Loss on lease exit*   915       9,055       1,733       9,055  
Corporate adjustments**   1,372       626       7,991       3,871  
Adjusted Operating Income $ 39,107     $ 24,650     $ 67,163     $ 38,301  
Adjusted Operating Income Margin   24.2 %     20.1 %     16.3 %     12.0 %

*    Represents exit costs due to exiting leases of certain facilities.
**    Corporate adjustments for the three and nine months ended March 31, 2023 relate to costs associated with secondary offerings completed in December 2022 (“December 2022 Secondary Offering”) and September 2022 (“September 2022 Secondary Offering”) of $— million and $2.2 million, respectively, professional, consulting, and other costs of $1.0 million and $3.5 million, respectively, and transaction expenses and other costs of $0.4 million and $2.3 million, respectively. Corporate adjustments for the three and nine months ended March 31, 2022 relate to certain restructuring costs of $0.2 million and $0.4 million, respectively, as well as costs associated with becoming a public company, including the implementation of a new enterprise-resource planning system and professional, consulting, and other costs of $0.4 million and $2.5 million, respectively, and costs associated with a secondary offering completed in October 2021 (“October 2021 Secondary Offering”) of $— million and $1.0 million, respectively.

Adjusted Operating Expenses (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Sales and Marketing expense $ 55,499     $ 41,487     $ 155,607     $ 127,957  
Amortization of intangible assets   (756 )           (2,823 )      
Stock-based compensation expense   (8,311 )     (7,634 )     (24,408 )     (29,390 )
Corporate adjustments*                     (53 )
Adjusted Sales and Marketing expense $ 46,432     $ 33,853     $ 128,376     $ 98,514  
General and Administrative expense $ 51,033     $ 54,090     $ 151,405     $ 141,963  
Amortization of intangible assets   (22,353 )     (20,703 )     (65,801 )     (61,531 )
Stock-based compensation expense   (7,168 )     (5,846 )     (19,765 )     (16,947 )
Loss on lease exit**   (915 )     (9,055 )     (1,733 )     (9,055 )
Corporate adjustments***   (1,372 )     (626 )     (7,991 )     (3,818 )
Adjusted General and Administrative expense $ 19,225     $ 17,860     $ 56,115     $ 50,612  
Research and Development expense $ 13,658     $ 9,324     $ 39,935     $ 30,120  
Stock-based compensation expense   (2,465 )     (1,104 )     (7,091 )     (3,779 )
Adjusted Research and Development expense $ 11,193     $ 8,220     $ 32,844     $ 26,341  

*    Corporate adjustments for the nine months ended March 31, 2022 relate to costs associated with becoming a public company.
**    Represents exit costs due to exiting leases of certain facilities.        
***    Corporate adjustments for the three and nine months ended March 31, 2023 relate to costs associated with the December 2022 Secondary Offering and the September 2022 Secondary Offering of $— million and $2.2 million, respectively, professional, consulting, and other costs of $1.0 million and $3.5 million, respectively, and transaction expenses and other costs of $0.4 million and $2.3 million, respectively. Corporate adjustments for the three and nine months ended March 31, 2022 relate to certain restructuring costs of $0.2 million and $0.4 million, respectively, as well as costs associated with becoming a public company, including the implementation of a new enterprise-resource planning system and professional, consulting, and other costs of $0.4 million and $2.4 million, respectively, and costs associated with the October 2021 Secondary Offering of $— million and $1.0 million, respectively.

Adjusted Net Income Attributable to Paycor HCM, Inc. and Adjusted Net Income Attributable to Paycor HCM, Inc. Per Share (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Net loss before benefit for income taxes $ (7,998 )   $ (23,574 )   $ (73,937 )   $ (108,402 )
Loss on debt amendment                     35  
Amortization of intangible assets   24,467       22,136       72,410       79,548  
Naming rights accretion expense   1,884             3,198        
Gain on installment sale                     (1,359 )
Stock-based compensation expense   20,384       16,294       58,019       55,321  
Loss on lease exit*   915       9,055       1,733       9,055  
Corporate adjustments**   1,372       626       7,991       3,871  
Non-GAAP adjusted income before applicable income taxes   41,024       24,537       69,414       38,069  
Income tax effect on adjustments***   (9,435 )     (5,889 )     (15,965 )     (9,137 )
Adjusted Net Income Attributable to Paycor HCM, Inc. $ 31,589     $ 18,648     $ 53,449     $ 28,932  
               
Adjusted Net Income Attributable to Paycor HCM, Inc. Per Share $ 0.18     $ 0.11     $ 0.30     $ 0.17  
Adjusted shares outstanding****   176,499,160       175,116,109       176,211,488       173,269,703  
               

*    Represents exit costs due to exiting leases of certain facilities.
**    Corporate adjustments for the three and nine months ended March 31, 2023 relate to costs associated with the December 2022 Secondary Offering and the September 2022 Secondary Offering of $— million and $2.2 million, respectively, professional, consulting, and other costs of $1.0 million and $3.5 million, respectively, and transaction expenses and other costs of $0.4 million and $2.3 million, respectively. Corporate adjustments for the three and nine months ended March 31, 2022 relate to certain restructuring costs of $0.2 million and $0.4 million, respectively, as well as costs associated with becoming a public company, including the implementation of a new enterprise-resource planning system and professional, consulting, and other costs of $0.4 million and $2.5 million, respectively, and costs associated with the October 2021 Secondary Offering of $— million and $1.0 million, respectively.
***    Non-GAAP adjusted income before applicable income taxes is tax effected using an adjusted effective income tax rate of 23.0% for the three and nine months ended March 31, 2023, respectively, and 24.0% for the three and nine months ended March 31, 2022, respectively.
****    The adjusted shares outstanding for the three and nine months ended March 31, 2023 are based on the if-converted method and include potentially dilutive securities that are excluded from the U.S. GAAP dilutive net income per share calculation because including them would have an anti-dilutive effect. The adjusted shares outstanding for the three months ended March 31, 2022 are based on the if-converted method and include potentially dilutive securities that are excluded from the U.S. GAAP dilutive net income per share calculation because including them would have an anti-dilutive effect. The adjusted shares outstanding for the nine months ended March 31, 2022 assume the conversion of the Series A Preferred Stock as if it would have occurred on July 1, 2021, based on the if-converted method and include potentially dilutive securities that are excluded from the U.S. GAAP dilutive net income per share calculation because including them would have an anti-dilutive effect.

 

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Pearson augments nursing content with generative AI study tools to improve nursing education and address shortages

Published

on

pearson-augments-nursing-content-with-generative-ai-study-tools-to-improve-nursing-education-and-address-shortages

HOBOKEN, N.J., May 17, 2024 /PRNewswire/ — Pearson (FTSE: PSON.L), the world’s leading learning company, today announced the integration of AI study tools into its Nursing: A Concept-Based Approach to Learning series, the only nursing concepts curriculum built from the ground up as a comprehensive, cohesive learning system.

Pearson’s AI study tools combine the power of generative AI technology with trusted Pearson content to provide scaffolded, guided help when students are stuck on homework problems, and personalized explanations, summaries, and practice problems for more efficient studying.
“Integrating AI study tools into our concept-based nursing series enhances the learning experience, giving nursing students and nurse educators the resources they need to efficiently study and master course concepts,” said Anne Fahlgren, GM of Pearson’s professional portfolio. “This technology will help more nursing candidates prepare for and enter the workforce, while also giving nurse educators the means to scale their teaching further, addressing major challenges in nursing education and society.”
The AI study tools beta will be available both in Pearson+ eTextbook and the accompanying MyLab Nursing course in time for Fall 2024. MyLab is an interactive teaching and learning platform, backed by content from Pearson authors. The platform, with integrated eTextbook, allows instructors to design their course, assign homework and assessments, and monitor student progress in real time.
The US is experiencing shortages of nurses and nurse educators. The National Academy of Medicine’s 2021 report on The Future of Nursing: 2020-2030 notes that, in order to provide sufficient care for an aging population over the next decade, a substantial increase in the nursing workforce will be needed that can practice “in community-based settings with diverse populations that face a variety of lived experiences.” The NAM’s report also references hundreds of nursing faculty position vacancies that have contributed to tens of thousands of qualified applicants being turned away from nursing school admission due to the inability to adequately meet student demand.
Concept-based nursing curriculum is designed to focus on key concepts emphasizing a holistic understanding of nursing principles that can be applied across different patient populations, healthcare settings, and situations. This approach strengthens clinical reasoning skills in the course of patient care. Incorporating generative AI tools into Pearson’s concept-based nursing content supports nurse educators in scaling their teaching and students’ ability to study more efficiently.
Dr. Michelle Aebersold, University of Michigan School of Nursing Clinical Professor and contributor to Nursing: A Concept-Based Approach to Learning, said “Technological advancements like generative AI are transforming the nursing profession. The ability to adapt in a rapidly changing environment is a critical healthcare skill, whether it’s in the course of patient care or in preparing our future nurses for the workforce. The ability of the AI study tools to provide a more user-centered, customized experience is a huge benefit for our students. I’m glad they will have access to Pearson’s AI tools that accommodate the variety of ways students learn and provide personalized support in the moment students need it most. This is the future of individualized learning.”
A Fall 2023 survey of students using Pearson’s AI study tools beta showed strong levels of engagement, with 75% of respondents saying the tools were helpful or very helpful to their studies.
The inclusion of generative AI study tools further solidifies Pearson’s dedication to providing the most comprehensive and effective learning and teaching resources for nursing students and nurse educators across the US. Pearson’s AI study tools are already available in more than 30 Pearson Mastering titles and are set to be integrated into more than 40 Pearson+ eTextbooks and MyLab and Mastering titles across math, science, business, and nursing for August of 2024.
Pearson is committed to investing in the responsible application of AI to advance product innovation and enhance the learning experience to educate, certify, and credential students and the workforce.
Pearson product experts are available to demo the AI study tools for members of the media. Please request demonstrations with the media contact below.
About Pearson
At Pearson, our purpose is simple: to add life to a lifetime of learning. We believe that every learning opportunity is a chance for a personal breakthrough. That’s why our c. 18,000 Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world’s leading learning company, serving customers in nearly 200 countries with digital content, assessments, qualifications, and data. For us, learning isn’t just what we do. It’s who we are. Visit us at pearsonplc.com.
Media [email protected]
Logo – https://mma.prnewswire.com/media/617186/Pearson_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/pearson-augments-nursing-content-with-generative-ai-study-tools-to-improve-nursing-education-and-address-shortages-302147855.html

Continue Reading

Artificial Intelligence

Brainomix Achieves Breakthrough with FDA Clearance of e-Lung AI Software

Published

on

brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software

Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space.With this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.OXFORD, England, and CHICAGO, May 17, 2024 /PRNewswire/ — Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, is proud to announce the FDA clearance of its latest product, Brainomix 360 e-Lung. Brainomix’s entry into the lung imaging space follows a series of successful clearances and widespread clinical adoption of its Brainomix 360 Stroke platform in both the US and Europe.

The clearance of e-Lung marks a significant milestone in Brainomix’s journey to expand its footprint in medical imaging beyond stroke-related applications and represents a notable step forward in the quest for advanced lung imaging solutions. The company, with its rich academic heritage and record of scientific excellence, will expand its research collaborations in the pulmonology space to yield new insights to inform future iterations of e-Lung and chart a path towards continual improvements for the lung imaging technology.
Dr Deji Adegunsoye, Assistant Professor of Medicine and Scientific Director of the Interstitial Lung Disease Program at University of Chicago Medicine, said: “This is an exciting step for Brainomix, who have a demonstrated track record of developing novel AI-based solutions in stroke and are now applying that expertise to develop innovative tools in the lung space. The preliminary data for e-Lung is impressive and would indicate that we have a promising tool that could help to expedite healthcare delivery and improve clinically meaningful outcomes for patients with lung disease.”
Brainomix recently announced the publication of a new study1 in the prestigious peer-reviewed journal American Journal of Respiratory and Critical Care Medicine (AJRCCM), resulting from a research collaboration with AstraZeneca. The results showed that Brainomix’s proprietary lung imaging biomarkers, which include the weighted reticulovascular score (WRVS), stratified patients at risk of Idiopathic Pulmonary Fibrosis (IPF) progression, outperforming standard measures.
Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: “We are harnessing our expertise in AI-powered imaging to develop novel biomarkers in other disease indications where AI can support imaging-based diagnostic and treatment decisions.
“This e-Lung FDA clearance reflects our focus on developing innovative solutions that empower healthcare professionals with cutting-edge tools for sophisticated disease evaluation, enhancing access to treatments that can ultimately work to improve patient outcomes.”
Brainomix will be presenting its latest e-Lung data at the American Thoracic Society (ATS) annual conference in San Diego May 17th – 22nd, including results from research collaborations with Heidelberg University and with Seattle-based Avalyn Pharma.
Am. J. Respir. Crit. Care Med.: 2024 Feb 16 – e-Lung CT Biomarker Stratifies Patients at Risk of IPF Progression in a 52-Week Clinical Trialhttps://www.atsjournals.org/doi/abs/10.1164/rccm.202312-2274LEAbout Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.
To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.
Contacts
Jeff Wyrtzen, Chief Marketing & Business Development [email protected] +44 (0)7927 164210T +44 (0)1865 582730
Media enquiries
Charles ConsultantsSue [email protected] M +44 (0)7968 726585
Logo – https://mma.prnewswire.com/media/1989193/3856380/Brainomix_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software-302144836.html

Continue Reading

Artificial Intelligence

CUBE acquires global regulatory intelligence businesses from Thomson Reuters

Published

on

cube-acquires-global-regulatory-intelligence-businesses-from-thomson-reuters

LONDON, May 17, 2024 /PRNewswire/ — CUBE, a global leader in Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM), announces today its acquisition of the Thomson Reuters Regulatory Intelligence and Oden products and businesses.

The acquisition of these global businesses represents a major step forward in CUBE’s growth plans. It will deliver significant scale across many of the world’s leading and systemically important financial institutions. CUBE’s existing global customer base will be expanded to total approximately 1,000 customers in banking, insurance, asset and investment management, payments and adjacent regulated industries.
CUBE’s global employees will expand to 600, of which close to 250 are highly qualified regulatory subject matter experts, legal and compliance professionals.
Ben Richmond, founder and CEO of CUBE said: “Thomson Reuters is known to be the biggest and best in the industry for providing regulatory expert analysis and subject matter expertise, alongside world-leading journalism and news. The combination of CUBE’s purpose-built AI, with the years of content curated by Thomson Reuters Regulatory Intelligence and Oden expert analysts, will accelerate innovation. Together, we will deliver regulatory transformation capabilities for our global customers that could only have been imagined before.”
Richmond continues: “This combination will provide tremendous scale and depth across CUBE’s regulatory content and technology. It is a significant step toward creating an industry-defining regulatory compliance and risk platform that will benefit all customers and elevate the industry as a whole.”
Through this acquisition, CUBE will provide an expanded and comprehensive selection of specialized regulatory intelligence and regulatory change services, committed to excellence, quality, and highly contextualised and meaningful regulatory content for customers. By combining cutting-edge technology and subject matter expertise at scale CUBE will set a new bar for the industry in regulatory automation and content.
Chris Maguire, General Manager, Risk and Fraud, Corporates, Thomson Reuters said: “It was clear to us that CUBE had established itself as a leading regulatory intelligence provider for global enterprise clients in the financial services and insurance sectors. We wanted to ensure our customers and employees could work with an organisation that would continue to innovate and significantly invest in solutions like Thomson Reuters Regulatory Intelligence and Oden. We are working tirelessly to ensure a seamless and value-enhancing transition for customers and employees, and we are looking forward to working with the CUBE team during this transition.” 
Christopher Fielding, Hg, said: “We’re delighted to further extend our market reach, bringing in two high quality and complementary global businesses to the CUBE platform.”
Thomas Martin, Hg, added: “We see these acquisitions as enabling further innovation in the regulatory intelligence and change management sector, leading to strengthened demand for these quality solutions across the globe.”
The terms of the transaction will not be disclosed.
About CUBE
CUBE provides a highly comprehensive and robust source of classified, and meaningful AI-driven regulatory data to power its Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM) solutions. CUBE’s purpose-built regulatory technology including its AI engine (RegBrain) and software platform (RegPlatform) tracks, analyses, and monitors laws, rules, and regulations in every country and in every published language to create an always up-to-date regulatory footprint that transforms visibility and compliance capability for customers across the globe.
With operations across Europe, North America, Canada, Asia, and Australia, CUBE serves a diverse and global base of customers and partners including the largest financial institutions in the world who leverage CUBE’s platform to streamline their complex regulatory intelligence and change management processes.
Following the strategic partnership with Hg in March 2024, CUBE announced the acquisition of US-based Reg-Room in May 2024.
About Hg
Hg supports the building of sector-leading enterprises that supply businesses with critical software applications or workflow services, delivering a more automated workplace for their customers.
This industry is characterised by digitisation trends that are in early stages of adoption and are set to transform the workplace for professionals over decades to come. Hg’s support combines deep end-market knowledge with world class operational resources, together providing compelling support to entrepreneurial leaders looking to scale their business – businesses that are well invested, enduring and serve their customers well.
With a vast European network and strong presence across North America, Hg’s 400 employees and around $70 billion in funds under management support a portfolio of around 50 businesses, worth over $140 billion aggregate enterprise value, with over 110,000 employees, consistently growing revenues at more than 20%.
About Regulatory Intelligence
Regulatory Intelligence is a proactive, connected, and comprehensive solution that tracks and analyses regulatory changes within ~2,000 regulatory bodies and rulebooks for more than 20 countries. It enables banking, financial services, and insurance (BFSI) sectors to manage exposure to operational, regulatory, and compliance risk.
About Oden
Oden State Rules and Regulations (SR&R), Oden Policy Terminator/Sentry PT, and OdenTrack provide repositories and automated solutions for complying with state rules and regulations on the provisioning of Personal and Business Insurance in the US.

View original content:https://www.prnewswire.co.uk/news-releases/cube-acquires-global-regulatory-intelligence-businesses-from-thomson-reuters-302147604.html

Continue Reading

Trending